Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10490
Title: Cost-effectiveness analysis of parenteral antimicrobials for acute melioidosis in Thailand.
Authors: Hantrakun, Viriya
Chierakul, Wirongrong
Chetchotisakd, Ploenchan
Anunnatsiri, Siriluck
Currie, Bart J
Peacock, Sharon J
Day, Nicholas P J
Cheah, Phaik Yeong
Cheah, Phaik
Limmathurotsakul, Direk
Lubell, Yoel
Affiliation: Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand viriya@tropmedres.ac..
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand..
Melioidosis Research Centre, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 4002, Thailand..
Melioidosis Research Centre, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 4002, Thailand..
Royal Darwin Hospital and Menzies School of Health Research, Darwin, Northern Territory 0811, Australia..
Department of Medicine, University of Cambridge, Cambridge, CB2 1TN, UK..
Center for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7LE, UK..
Center for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7LE, UK..
Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand..
Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand..
Issue Date: Jun-2015
Citation: Transactions of the Royal Society of Tropical Medicine and Hygiene 2015-06; 109(6): 416-8
Abstract: Melioidosis is a common community-acquired infectious disease in northeast Thailand associated with overall mortality of approximately 40% in hospitalized patients, and over 70% in severe cases. Ceftazidime is recommended for parenteral treatment in patients with suspected melioidosis. Meropenem is increasingly used but evidence to support this is lacking. A decision tree was used to estimate the cost-effectiveness of treating non-severe and severe suspected acute melioidosis cases with either ceftazidime or meropenem. Empirical treatment with meropenem is likely to be cost-effective providing meropenem reduces mortality in severe cases by at least 9% and the proportion with subsequent culture-confirmed melioidosis is over 20%. In this context, treatment of severe cases with meropenem is likely to be cost-effective, while the evidence to support the use of meropenem in non-severe suspected melioidosis is not yet available.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10490
DOI: 10.1093/trstmh/trv002
Type: Journal Article
Research Support, Non-U.S. Gov't
Subjects: Antimicrobials
Ceftazidime
Cost-effective treatment
Meliodosis
Meropenem
Northeast Thailand
Anti-Infective Agents
Ceftazidime
Cost-Benefit Analysis
Female
Humans
Male
Melioidosis
Thailand
Thienamycins
Treatment Outcome
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.